Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Deliberate Obfuscation

<< Previous

Bullboard Posts

Next >>

Comment by Rumpl3StiltSkinon Jun 13, 2022 5:18pm

155 Views

Post# 34753424

RE:RE:RE:RE:RE:RE:RE:RE:RE:Deliberate Obfuscation

Yep a huge opportunity to buy. newb TLT investors can load up here for cheap. :-) As painful as this is for us long term guys/gals. I have to agree, TLT share price went down with the market. Not just today either...

ScienceFirst wrote:
LS29 ... Th magg et key is tanking. Nothing related to TLT.

We all know we're advancing toward something interesting and pivotal if data continues a positive trend. Management has brought us here, on the verge of a projected Breakthrough designation late 2022 and projected commercial revenues early 2023, so being impatient won't change anything. They know more than us and the recent buying of Roger and Kristina should calm you as at this time, it's more than a positive signal, given all they know about the clinical data of Ph. 2b patients.

This pullback is just another of those many golden opportunities to add more if you so believe in this stock.